Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models

Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models

<i>Col4a3<sup>−/−</sup></i> Alport mice serve as an animal model for renal fibrosis. MicroRNA-21 (miR-21) expression has been shown to be increased in the kidneys of Alport syndrome patients. Here, we investigated the nephroprotective effects of Lademirsen anti-miR-21 therapy...

Full description

Bibliographic Details
Main Authors: Diana Rubel, Joseph Boulanger, Florin Craciun, Ethan Y. Xu, Yanqin Zhang, Lucy Phillips, Michelle Callahan, William Weber, Wenping Song, Nicholas Ngai, Nikolay O. Bukanov, Xingyi Shi, Ali Hariri, Hervé Husson, Oxana Ibraghimov-Beskrovnaya, Shiguang Liu, Oliver Gross
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cells
Subjects:
nephroprotection
renal fibrosis
type IV collagen
Alport syndrome
microRNA-21
podocytopathies
Online Access:https://www.mdpi.com/2073-4409/11/4/594

Internet

https://www.mdpi.com/2073-4409/11/4/594

Similar Items